Retaspimycin

Base Information

• Chemical Name: Retaspimycin
• CAS No.: 857402-23-4
• Molecular Formula: C31H45 N3 O8
• Molecular Weight: 587.714
• UNII: BZF2ZM0I5Z
• ChEMBL ID: CHEMBL1184904
• DSSTox Substance ID: DTXSID70870378
• Metabolomics Workbench ID: 65891
• NCI Thesaurus Code: C80378
• Nikkaji Number: J2.321.924G
• Wikidata: Q27139837

Synonyms:17-(allylamino)-17-demethoxy-geldanamycin;17-(allylamino)-17-demethoxygeldanamycin;17-AAG;17-allyl-aminogeldanamycin;17-allylamino-17-demethoxygeldanamycin;17-allylamino-17-demethoxygeldanamycin hydroquinone;17-allylamino-17-demethoxygeldanamycin hydroquinone salt;17-allylamino-geldanamycin;17-allylaminogeldanamycin;17-N-allylamino-17-demethoxygeldanamycin;17AAG;CNF1010;IPI 493;IPI 504;IPI-493;IPI-504;IPI493;IPI504;NSC 330507;NSC-330507;retaspimycin hydrochloride;tanespimycin

Chemical Property of Retaspimycin

Chemical Property:

• Boiling Point: 800.9±65.0 °C(Predicted)
• PKA: 10.15±0.70(Predicted)
• PSA: 172.60000
• Density: 1.23
• LogP: 5.06750
• Solubility.: Soluble in DMSO
• XLogP3: 3.4
• Hydrogen Bond Donor Count: 6
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 7
• Exact Mass: 587.32066540
• Heavy Atom Count: 42
• Complexity: 999

Purity/Quality:

97% ^*data from raw suppliers

Retaspimycin 98+% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)C)OC)OC(=O)N)C)C)O)OC
• Isomeric SMILES: C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)/C)OC)OC(=O)N)\C)C)O)OC
• Recent ClinicalTrials: IPI-504 in NSCLC Patients With ALK Translocations
• Recent EU Clinical Trials: Un estudio de fase 2 multicéntrico para evaluar la eficacia y seguridad del IPI-504 en combinación con trastuzumab en pacientes con cáncer de mama pretratado, localmente avanzado o metastásico, positivo para el receptor 2 del factor de crecimiento epidérmico humano (HER2)
• Description: Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.
• Uses: Retaspimycin (IPI-504) was previously under development by manufacturer Infinity Pharmaceuticals in conjunction with MedImmune, a part of AstraZeneca. Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis. Orphan drug designation was assigned to the compound by the FDA for the treatment of gastrointestinal stromal cancer (GIST). Infinity Pharmaceuticals has discontinued the development of retaspimycin (IPI-504) an inhibitor of the HSP-90) complex, for the treatment of cancer due to lack of efficacy in 1913.

Technology Process of Retaspimycin

There total 1 articles about Retaspimycin which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 90.0%

17-allylamino-17-demethoxygeldanamycin (75747-14-7) → (4E,6Z,8S,9S,10E,12S,13R,14S,16R)‐19‐(allylamino)‐13,20,22‐trihydroxy‐8,14‐dimethoxy‐4,10,12,16‐tetramethyl‐3‐oxo‐2‐azabicyclo[1 6.3.1]docosa‐1(22),4,6,10,18,20‐hexaen‐9‐yl carbamate (857402-23-4)

Guidance literature:

With sodium dithionite; water; In ethyl acetate; for 0.5h;

Reference yield:

(4E,6Z,8S,9S,10E,12S,13R,14S,16R)‐19‐(allylamino)‐13,20,22‐trihydroxy‐8,14‐dimethoxy‐4,10,12,16‐tetramethyl‐3‐oxo‐2‐azabicyclo[1 6.3.1]docosa‐1(22),4,6,10,18,20‐hexaen‐9‐yl carbamate (857402-23-4) + 2-bromoacetyl chloride (22118-09-8) → C33H45N3O9

Guidance literature:

(4E,6Z,8S,9S,10E,12S,13R,14S,16R)‐19‐(allylamino)‐13,20,22‐trihydroxy‐8,14‐dimethoxy‐4,10,12,16‐tetramethyl‐3‐oxo‐2‐azabicyclo[1 6.3.1]docosa‐1(22),4,6,10,18,20‐hexaen‐9‐yl carbamate; 2-bromoacetyl chloride; In ethyl acetate; at 20 ℃; for 12h;

With sodium carbonate; In tetrahydrofuran; water; for 1h;

Reference yield:

(4E,6Z,8S,9S,10E,12S,13R,14S,16R)‐19‐(allylamino)‐13,20,22‐trihydroxy‐8,14‐dimethoxy‐4,10,12,16‐tetramethyl‐3‐oxo‐2‐azabicyclo[1 6.3.1]docosa‐1(22),4,6,10,18,20‐hexaen‐9‐yl carbamate (857402-23-4) + bis(trichloromethyl) carbonate (32315-10-9) → C32H43N3O9

Guidance literature:

In ethyl acetate; at 20 ℃; for 2h;

upstream raw materials:

17-allylamino-17-demethoxygeldanamycin

Post a RFQ

Cas No.:

Product Name:

Quantity:

Please select Metric Ton KG G Pound L ML

Email:

Company name:

Valid Period:

Detailed Requirements:

• Sample
• MOQ
• GMP
• FDA
• Price
  FOB CIF CFR EXW
• Urgent purchase

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Remove

Submit

1

What can I do for you?
Get Best Price

Get Best Price for 857402-23-4 Retaspimycin

Send

Send

Metric Ton KG G Pound L ML

Send

Send